Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
43.3800 +0.4700 (+1.10%) 03/25/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 43.3800 unch (unch) 16:00 ET
Quote Overview for Tue, Mar 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
42.9300
Day High
43.8400
Open 43.5900
Previous Close 42.9100 42.9100
Volume 1,404,800 1,404,800
Avg Vol 5,734,215 5,734,215
Stochastic %K 62.16% 62.16%
Weighted Alpha +37.00 +37.00
5-Day Change -0.6800 (-1.54%) -0.6800 (-1.54%)
52-Week Range 29.2000 - 44.3100 29.2000 - 44.3100
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 273,677,248
  • Shares Outstanding, K 6,377,936
  • Annual Sales, $ 68,726 M
  • Annual Income, $ 9,403 M
  • EBIT $ 0 M
  • EBITDA $ 21,007 M
  • 60-Month Beta 0.41
  • Price/Sales 4.06
  • Price/Cash Flow 13.61
  • Price/Book 7.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/06/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.847 on 03/14/24
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.1700 +5.37%
on 02/28/25
Period Open: 41.7900
44.3100 -2.10%
on 03/17/25
+1.5900 (+3.80%)
since 02/25/25
3-Month
34.7100 +24.98%
on 12/26/24
Period Open: 34.9600
44.3100 -2.10%
on 03/17/25
+8.4200 (+24.08%)
since 12/24/24
52-Week
29.2000 +48.56%
on 05/02/24
Period Open: 31.2900
44.3100 -2.10%
on 03/17/25
+12.0900 (+38.64%)
since 03/25/24

Most Recent Stories

More News
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame,...

NVO : 73.60 (-2.30%)
LLY : 852.35 (-1.45%)
RHHBY : 43.3800 (+1.10%)
AMGN : 306.86 (-2.39%)
2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%

These smaller stocks may carry more risk, but they also carry greater reward potential.

NVDA : 120.69 (-0.59%)
BAYRY : 6.3400 (+4.79%)
RXRX : 6.53 (-3.83%)
ARDX : 5.19 (-1.14%)
RHHBY : 43.3800 (+1.10%)
SNY : 55.45 (-0.86%)
The Best Vanguard ETF to Invest $1,000 in Right Now

What to invest in now -- that may seem like a tough decision, given the current economic uncertainty in the U.S. including ongoing tariff-related concerns. Investors are worried about inflation, about...

SONY : 25.26 (-0.04%)
SAP : 280.23 (+1.63%)
SPGI : 513.16 (+1.83%)
NVS : 110.38 (-0.64%)
RHHBY : 43.3800 (+1.10%)
VIGI : 84.81 (+0.22%)
NSRGY : 100.7000 (-0.76%)
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic...

ALNY : 280.96 (-3.35%)
NVS : 110.38 (-0.64%)
REGN : 634.14 (-4.06%)
RHHBY : 43.3800 (+1.10%)
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped

Ignore the noise in GLP-1 stocks. Find the best value instead.

VKTX : 27.98 (-4.44%)
NVO : 73.60 (-2.30%)
LLY : 852.35 (-1.45%)
RHHBY : 43.3800 (+1.10%)
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug

Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an obesity candidate.Per the terms of the agreement, both companies will develop...

NVO : 73.60 (-2.30%)
LLY : 852.35 (-1.45%)
RHHBY : 43.3800 (+1.10%)
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More

This week, Bayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm Gubra for an amylin-targeting obesity treatment, which marked the...

BAYRY : 6.3400 (+4.79%)
NVO : 73.60 (-2.30%)
JNJ : 161.02 (-1.39%)
ABBV : 201.34 (-3.74%)
RHHBY : 43.3800 (+1.10%)
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults.As a...

BMRN : 71.53 (-0.64%)
GILD : 107.89 (+1.08%)
RHHBY : 43.3800 (+1.10%)
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).The...

BMRN : 71.53 (-0.64%)
GILD : 107.89 (+1.08%)
REGN : 634.14 (-4.06%)
RHHBY : 43.3800 (+1.10%)
NovoCure Q4 EPS Misses, Revenue Matches

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

NVCR : 18.77 (-5.11%)
MRK : 87.87 (-4.81%)
ZLAB : 35.40 (-0.76%)
RHHBY : 43.3800 (+1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 44.7467
2nd Resistance Point 44.2933
1st Resistance Point 43.8367
Last Price 43.3800
1st Support Level 42.9267
2nd Support Level 42.4733
3rd Support Level 42.0167

See More

52-Week High 44.3100
Last Price 43.3800
Fibonacci 61.8% 38.5380
Fibonacci 50% 36.7550
Fibonacci 38.2% 34.9720
52-Week Low 29.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals